ANDA 78453, held by Orbion Pharmaceuticals. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 78453 (Amlodipine Besylate), held by Orbion Pharmaceuticals, was first approved by FDA on Jul 2, 2009, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2009 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE ยท tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 5MG BASE ยท tablet;oral | Amlodipine Besylate | Rx |
| Amlodipine BesylateEQ 10MG BASE ยท tablet;oral | Amlodipine Besylate | Rx |
| Apr 25, 2018 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Apr 25, 2018 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Oct 7, 2015 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Oct 26, 2014 | Supplement 2Labeling | Approved | None posted |
| Oct 26, 2014 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Aug 29, 2011 | Supplement 1Labeling | Approved | None posted |
| Jul 2, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters